XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Preferred Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning Balances at Dec. 31, 2020 $ 58,693 $ 110 $ 0 $ 1,352,374 $ 273 $ (1,294,064)
Beginning Balances (in shares) at Dec. 31, 2020   110,190 4      
Issuance of common stock upon exercise of stock options and restricted stock awards, net 1,335     1,335    
Issuance of common upon exercise of stock options and restricted stock awards, net (in shares)   833        
Exercise of warrants 7,928 $ 1   7,927    
Exercise of warrants, shares   750        
Issuance of common stock under Employee Stock Purchase Plan 383     383    
Issuance of common stock under Employee Stock Purchase Plan (in shares)   104        
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement 28,156 $ 3   28,153    
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)   2,879        
Purchase of capped call options related to issuance of Convertible Notes (27,240)     (27,240)    
Stock compensation expense 9,747     9,747    
Total other comprehensive income (Loss) (986)       (986)  
Net income 5,364         5,364
Ending Balances at Jun. 30, 2021 83,380 $ 114 $ 0 1,372,679 (713) (1,288,700)
Ending Balances (in shares) at Jun. 30, 2021   114,756 4      
Beginning Balances at Mar. 31, 2021 99,762 $ 114 $ 0 1,393,947 (1,126) (1,293,173)
Beginning Balances (in shares) at Mar. 31, 2021   114,563 4      
Issuance of common stock upon exercise of stock options and restricted stock awards, net 948     948    
Issuance of common upon exercise of stock options and restricted stock awards, net (in shares)   193        
Purchase of capped call options related to issuance of Convertible Notes (27,240)     (27,240)    
Stock compensation expense 5,024     5,024    
Total other comprehensive income (Loss) 413       413  
Net income 4,473         4,473
Ending Balances at Jun. 30, 2021 83,380 $ 114 $ 0 1,372,679 (713) (1,288,700)
Ending Balances (in shares) at Jun. 30, 2021   114,756 4      
Beginning Balances at Dec. 31, 2021 222,374 $ 123 $ 0 1,441,868 (2,266) (1,217,351)
Beginning Balances (in shares) at Dec. 31, 2021   122,945 0      
Issuance of common stock upon exercise of stock options and restricted stock awards, net 2,150 $ 1   2,149    
Issuance of common upon exercise of stock options and restricted stock awards, net (in shares)   1,533        
Issuance of common stock upon exercise of warrants (Shares)   1,879        
Issuance of common stock upon exercise of warrants 24,670 $ 2   24,668    
Issuance of common stock under Employee Stock Purchase Plan 710     710    
Issuance of common stock under Employee Stock Purchase Plan (in shares)   82        
Stock compensation expense 15,575     15,575    
Total other comprehensive income (Loss) (4,294)       (4,294)  
Net income 161,614         161,614
Ending Balances at Jun. 30, 2022 422,799 $ 126 $ 0 1,484,970 (6,560) (1,055,737)
Ending Balances (in shares) at Jun. 30, 2022   126,439 0      
Beginning Balances at Mar. 31, 2022 287,484 $ 126 $ 0 1,476,013 (4,163) (1,184,492)
Beginning Balances (in shares) at Mar. 31, 2022   126,297 0      
Issuance of common stock upon exercise of stock options and restricted stock awards, net 1,028     1,028    
Issuance of common upon exercise of stock options and restricted stock awards, net (in shares)   142        
Stock compensation expense 7,929     7,929    
Total other comprehensive income (Loss) (2,397)       (2,397)  
Net income 128,755         128,755
Ending Balances at Jun. 30, 2022 $ 422,799 $ 126 $ 0 $ 1,484,970 $ (6,560) $ (1,055,737)
Ending Balances (in shares) at Jun. 30, 2022   126,439 0